U.S. Weightlifting Athlete Rowdy Hurst Receives Sanction for Anti-Doping Rule Violation

USADA announced today that Rowdy Hurst, of West Bountiful, Utah, an athlete in the sport of weightlifting, has received a four-year suspension for an anti-doping rule violation.

 

Hurst, 29, tested positive for an exogenous anabolic agent, clomiphene and its metabolites, and modafinil and its metabolite modafinil acid, as a result of an in-competition drug test conducted at the American Open Finals on December 7, 2019.

 

His urine sample was analyzed using a specialized test that differentiates between anabolic androgenic steroids (AAS), which are produced naturally by the body, and prohibited anabolic agents of external origin. Anabolic agents have powerful performance-enhancing capabilities and can give an athlete an unfair advantage over fellow competitors.

 

All AAS are non-Specified Substances in the class of Anabolic Agents. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators, and modafinil is a non-Specified Substance in the class of Stimulants. Modafinil is prohibited in-competition, while AAS and clomiphene are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Policy, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency (WADA) Prohibited List.

 

Hurst received a four-year period of ineligibility that began on January 16, 2020, the date his provisional suspension was imposed.

 

In addition, Hurst has been disqualified from competitive results obtained on and subsequent to December 7, 2019, the date his positive sample was collected, including forfeiture of any medals, points and prizes.